drugset / Trial / NCT02988817
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
NaSequentialOpen-labelTreatment
Summary
The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors
Timeline
- Start
- 2016-11-23
- Primary completion
- 2021-11-12
- Completion
- 2021-11-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enapotamab vedotin | Unknown | — | Intravenous |